Need professional-grade analysis? Visit stockanalysis.com
$12.05B
N/A
N/A
N/A
Summit Therapeutics PLC (SMMT) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $15.54, up 0.19% from the previous close.
Over the past year, SMMT has traded between a low of $13.85 and a high of $36.70. The stock has lost 21.9% over this period. It is currently 57.7% below its 52-week high.
Summit Therapeutics PLC has a market capitalization of $12.05B.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.